Immunotherapy of cancer in the era of checkpoint inhibitor

Inderjit Mehmi; Omid Hamid

doi:10.1007/s10585-021-10132-9

Immunotherapy of cancer in the era of checkpoint inhibitor

Clin Exp Metastasis. 2022 Feb;39(1):231-237. doi: 10.1007/s10585-021-10132-9. Epub 2021 Dec 8.

Authors

Inderjit Mehmi¹, Omid Hamid²

Affiliations

¹ The Angeles Clinic and Research Institute, Cedar Sinai Affiliate, Los Angeles, CA, USA. imehmi@theangelesclinic.org.
² The Angeles Clinic and Research Institute, Cedar Sinai Affiliate, Los Angeles, CA, USA.

PMID: 34878618
DOI: 10.1007/s10585-021-10132-9

Abstract

Application of immunotherapy has revolutionized treatment of number of malignancies. We present a review of immunotherapy approaches, early-phase data of number of new immunotherapeutic targets in melanoma, cutaneous squamous cell carcinoma, Merkel cell cancer, and non-small cell lung cancer.

Keywords: Checkpoint inhibitors; Cytokines; Immunotherapy; LAG-3; MCC; Melanoma; NSCLC; TIM-3; cSCC.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Squamous Cell* / drug therapy
Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Skin Neoplasms* / drug therapy